Evidence map›Paper›PMID 29971529›Full record

ArticleDiabetologia2018

Bioengineered human pseudoislets form efficiently from donated tissue, compare favourably with native islets in vitro and restore normoglycaemia in mice.

Yang Yu, Anissa Gamble, Rena Pawlick, Andrew R Pepper, Bassem Salama, Derek Toms, Golsa Razian, Cara Ellis, Antonio Bruni, Boris Gala-Lopez and 8 more

Abstract read
In one paragraph

Article in Diabetologia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Loss of tetraspanin-7 expression reduces pancreatic β-cell exocytosis CaDiabetic medicine : a journal of the British Diabetic Association · 2022
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Formation of Re-Aggregated Neonatal Porcine Islet Clusters ImprovesTransplant international : official journal of the European Society for Organ Transplantation · 2022
    Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Yang YuBiomedical Engineering Graduate Program, University of Calgary, Calgary, AB, Canada.
Anissa GambleAlberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada.
Rena PawlickAlberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada.
Andrew R PepperAlberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada.
Bassem SalamaAlberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada.
Derek TomsAlberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada.
Golsa RazianAlberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada.
Cara EllisAlberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada.
Antonio BruniAlberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada.
Boris Gala-LopezAlberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada.
Jia Lulu LuAlberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada.
Heather VovkoAlberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada.
Cecilia ChiuAlberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada.
Shaaban AbdoAlberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada.
Tatsuya KinClinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada.
Greg KorbuttAlberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada.
A M James ShapiroAlberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada.
Mark UngrinBiomedical Engineering Graduate Program, University of Calgary, Calgary, AB, Canada. mark.ungrin@ucalgary.ca.ORCID http://orcid.org/0000-0002-7410-1491

Funding

CIHR MOP-137095
6 · The paper itself

Abstract

aims/hypothesisIslet transplantation is a treatment option that can help individuals with type 1 diabetes become insulin independent, but inefficient oxygen and nutrient delivery can hamper islet survival and engraftment due to the size of the islets and loss of the native microvasculature. We hypothesised that size-controlled pseudoislets engineered via centrifugal-forced-aggregation (CFA-PI) in a platform we previously developed would compare favourably with native islets, even after taking into account cell loss during the process.

methodsHuman islets were dissociated and reaggregated into uniform, size-controlled CFA-PI in our microwell system. Their performance was assessed in vitro and in vivo over a range of sizes, and compared with that of unmodified native islets, as well as islet cell clusters formed by a conventional spontaneous aggregation approach (in which dissociated islet cells are cultured on ultra-low-attachment plates). In vitro studies included assays for membrane integrity, apoptosis, glucose-stimulated insulin secretion assay and total DNA content. In vivo efficacy was determined by transplantation under the kidney capsule of streptozotocin-treated Rag1

resultsCFA-PI exhibit markedly increased uniformity over native islets, as well as substantially improved glucose-stimulated insulin secretion (8.8-fold to 11.1-fold, even after taking cell loss into account) and hypoxia tolerance. In vivo, CFA-PI function similarly to (and potentially better than) native islets in reversing hyperglycaemia (55.6% for CFA-PI vs 20.0% for native islets at 500 islet equivalents [IEQ], and 77.8% for CFA-PI vs 55.6% for native islets at 1000 IEQ), and significantly better than spontaneously aggregated control cells (55.6% for CFA-PI vs 0% for spontaneous aggregation at 500 IEQ, and 77.8% CFA-PI vs 33.4% for spontaneous aggregation at 1000 IEQ; p < 0.05). Glucose clearance in the CFA-PI groups was improved over that in the native islet groups (CFA-PI 18.1 mmol/l vs native islets 29.7 mmol/l at 60 min; p < 0.05) to the point where they were comparable with the non-transplanted naive normoglycaemic control mice at a low IEQ of 500 IEQ (17.2 mmol/l at 60 min). CONCLUSIONS/

interpretationThe ability to efficiently reformat dissociated islet cells into engineered pseudoislets with improved properties has high potential for both research and therapeutic applications.

Indexed as

Islets of Langerhans TransplantationTissue EngineeringAnimalsApoptosisCell SurvivalDiabetes MellitusDiabetes Mellitus, ExperimentalDNAFemaleGene Expression ProfilingGlucoseGraft SurvivalHumansHyperglycemiaHypoxiaInsulinDNAGlucoseInsulinHypoxiaIsletMousePseudoisletTransplant

Identifiers

PMID29971529
PMCPMC6096633

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.